Amplification

Kognitiv Launches AI-Native, Outcome-Based Kognitiv Amplify

Retrieved on: 
Wednesday, March 27, 2024
Amplification, CRM, ROI, Marketing, Software as a service, Heart, Acquisition, CPA, Sales

Toronto, ON, March 27, 2024 (GLOBE NEWSWIRE) -- Kognitiv Corporation (“Kognitiv”) is thrilled to announce the addition of Kognitiv Amplify to its innovative omnichannel and omniaudience SaaS platform.

Key Points: 
  • Toronto, ON, March 27, 2024 (GLOBE NEWSWIRE) -- Kognitiv Corporation (“Kognitiv”) is thrilled to announce the addition of Kognitiv Amplify to its innovative omnichannel and omniaudience SaaS platform.
  • ​Kognitiv Amplify brings outcome-based planning, execution and optimization to paid media by driving relevancy and increasing conversions with AI-powered hyper personalization, cross-channel workflow automation, and real-time optimization.
  • “With Kognitiv Amplify, we’ve created a tool that will enable marketers to make better budgeting and planning decisions that will maximize their ROAS, while acquiring more and better customers at a lower CPA,” said Anthony Wintheiser, Chief Product Officer at Kognitiv.
  • “With Kognitiv Amplify, we are pleased to be delivering intelligent omnichannel and omniaudience ad optimization to help brands achieve their marketing and business goals with certainty​.”

New Report: Data Show K-2 Literacy Improvements Have Slowed, Overall Literacy Rates in the U.S. Remain a Concern

Retrieved on: 
Wednesday, March 13, 2024
Risk, Amplification, Student, School, Book, Research, News, Learning, Literacy, Achievement Medal, Curriculum, Caregiver, Tutoring

BROOKLYN, N.Y., March 13, 2024 /PRNewswire/ -- Amplify, a publisher of next-generation curriculum and assessment programs, today released a research brief on the latest middle-of-school-year reading data for K–2. Findings reveal that throughout the spring and fall of 2023, schools across the country made some progress increasing the number of K–2 students on track for learning to read, but that progress has slowed.

Key Points: 
  • Across grades K–2, only half of students are on track for learning to read, and three in ten students are far behind.
  • The data demonstrate how literacy rates in the United States remain a concern: Too many students are at risk of failing to read proficiently by the end of third grade, an important indicator of future academic success.
  • "The data is clear—literacy rates at the earliest and most critical time for student development are slowing.
  • Allocate staff to support students who are at risk, spending additional time in literacy instruction beyond grade-level instruction.

Ventris Medical Receives 510(k) Additional Clearance for Amplify® Standalone Bone Graft Putty

Retrieved on: 
Wednesday, March 13, 2024
Element, Amplification, Porosity, Cell proliferation, Tissue, Algorithm, FDA, Doctor of Philosophy, Fertilizer

NEWPORT BEACH, Calif., March 13, 2024 /PRNewswire/ -- Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the United States Food and Drug Administration has granted 510(k) clearance in the intervertebral disc space for Synthetic Bone Graft Putty (Amplify®).

Key Points: 
  • NEWPORT BEACH, Calif., March 13, 2024 /PRNewswire/ -- Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the United States Food and Drug Administration has granted 510(k) clearance in the intervertebral disc space for Synthetic Bone Graft Putty (Amplify®).
  • The device can be used either standalone or in combination with autograft bone (1:1 ratio) as a bone graft extender.
  • Russell Cook, CEO of Ventris Medical commented, "We are very pleased to receive FDA clearance for Amplify® Synthetic Bone Graft Putty for the intervertebral disc space.
  • This milestone sets the stage for future product developments and establishes Ventris as a key innovator in the orthobiologics space."

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Fast Track, Regenerative Medicine Advanced Therapy, Cancer Immunology Research, Research, CRISPR, Rachel Haurwitz, Doctor of Philosophy, Orphan drug, AML, FDA, Food, Reindeer, AACR, Manuscript, Bone marrow, Amplification, Patent, Patient, ASCT, Asian literature, Acute myeloid leukemia, G&A, IND, Insurance, Pharmaceutical industry

BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.

Key Points: 
  • “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
  • For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
  • In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
  • CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Retrieved on: 
Tuesday, March 5, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, General Health, Other Science, Science, Traffic barrier, EV, System, Blood, Cerebrospinal fluid, Neurological disorder, AUC, Amplification, Conference, Seminal vesicles, Biomarker, Patient, Dementia, DSM-IV codes, CSF, Disease, Diagnosis, PET, APEX, Brain, Medical imaging

The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.

Key Points: 
  • The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.
  • “These results provide further evidence that the APEX platform has the potential to offer highly sensitive and accurate Alzheimer’s disease diagnosis equivalent to PET scans from a simple blood draw,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • The APEX Aβ test is a blood-based diagnostic that uniquely detects very low levels of disease-specific proteins in blood with high accuracy.
  • EV-associated Aβ in blood are highly correlative and a direct reflection of Aβ build-up in the brain, a key abnormality in Alzheimer’s disease.

Say Hello to Amplify: Your New Legal Marketing Agency

Retrieved on: 
Thursday, February 29, 2024
Amplification, Lawyer, Brand Building, Organization, Creativity

MIAMI, Feb. 29, 2024 /PRNewswire/ -- Senior legal industry veterans launch Amplify , a new legal marketing agency uniquely positioned to elevate legal brands and redefine storytelling in the legal industry.

Key Points: 
  • MIAMI, Feb. 29, 2024 /PRNewswire/ -- Senior legal industry veterans launch Amplify , a new legal marketing agency uniquely positioned to elevate legal brands and redefine storytelling in the legal industry.
  • Amplify is a new legal marketing agency that elevates legal brands and redefines storytelling.
  • Amplify is not just a legal marketing agency; it promises a dynamic approach to shaping the narrative of law firms across the nation.
  • Traditional Legal Marketing Techniques: The Amplify team has decades of success transforming law firms' results through traditional legal marketing.

Amplify ETFs Appointed New Sponsor of BDRY and BWET

Retrieved on: 
Friday, February 16, 2024
BWET, Amplification, ETF, Trust

LISLE, Ill., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announces it will serve as the new sponsor of the Breakwave Dry Bulk Shipping ETF (BDRY™) and the Breakwave Tanker Shipping ETF (BWET™).

Key Points: 
  • LISLE, Ill., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announces it will serve as the new sponsor of the Breakwave Dry Bulk Shipping ETF (BDRY™) and the Breakwave Tanker Shipping ETF (BWET™).
  • “We’re pleased to add BDRY and BWET to the Amplify platform.
  • The two ETFs align with our existing suite while delivering further diversification to our set of solutions for investors,” said Christian Magoon, CEO of Amplify ETFs.
  • “We’re excited about the future for BDRY and BWET under Amplify’s direction and leadership.

M&T CHARITABLE FOUNDATION ANNOUNCES $8.2 MILLION IN GRANTS TO 68 NONPROFITS ACROSS NEW ENGLAND, LONG ISLAND, AND ROCKLAND COUNTY, NY

Retrieved on: 
Tuesday, February 13, 2024
RFF, Mental health, Woman, Education, United Bank, M&T Bank, Health, Youth, Tenant, Grief, YMHA, Literacy, People's United Financial, Education in Stamford, Connecticut, Fund, Organization, Infant, Amplification, Food security, Metro New York, Housing, MTB, Nursing

BUFFALO, N.Y., Feb. 13, 2024 /PRNewswire/ -- The M&T Charitable Foundation, the philanthropic arm of M&T Bank (NYSE: MTB), today announced $8.2 million in donations to 68 nonprofit organizations across New England and Long Island and Rockland County New York. The announcement is the second round of giving as part of the company's Amplify Fund grant, a commitment by M&T Bank to work with groups dedicated to addressing social issues through a racial equity and social justice lens in low- and moderate- income communities and underrepresented populations.

Key Points: 
  • First announced in May 2022 , the Amplify Fund is a $25 million philanthropic investment as part of the merger between People's United Bank and M&T Bank.
  • Powered by the M&T Charitable Foundation, the Amplify Fund is a one-time supplemental charitable giving program to provide further support in the legacy People's United communities.
  • Health Equity: Access to quality and affordable healthcare, with a priority on youth mental health and women and infant health.
  • "We are so honored to receive this transformational support from the M&T Charitable Foundation.

Lee Enterprises reports first quarter Adjusted EBITDA growth and strong digital growth

Retrieved on: 
Thursday, February 1, 2024
Pillar, Lee Enterprises, Advertising, Digital, Amplification, Adjustment, Marketing, Music

DAVENPORT, Iowa, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 73 markets, today reported preliminary first quarter fiscal 2024 financial results(4) for the period ended December 24, 2023.

Key Points: 
  • “Our Three Pillar Digital Growth Strategy is driving audience growth, improving consumer engagement, and increasing digital subscribers.
  • “Because of our impressive digital subscription revenue growth combined with solid gains at Amplified Digital®, digital revenue reached 46% of total operating revenue in the quarter.
  • We expect strong digital revenue combined with cost management execution to keep us on track to achieve our overall Adjusted EBITDA guidance for the full year," added Mowbray.
  • Digital services revenue, which is predominantly BLOX Digital, totaled $5 million in the quarter.

dbt Labs Names Data Industry Veteran Mark Porter as Chief Technology Officer

Retrieved on: 
Thursday, February 1, 2024
Cloud, Labs, Amplification, Growth, Knowledge, Workflow, Research, Boston Consulting Group, MongoDB, GitLab, Amazon Web Services, News Corp, Grab, Roche, Oracle Corporation, Engineering, Organization, Management

PHILADELPHIA, Feb. 1, 2024 /PRNewswire/ -- dbt Labs, the pioneer in analytics engineering, today announced the appointment of Mark Porter as Chief Technology Officer. Porter will lead dbt Labs' engineering organization including the development, research and infrastructure teams, supporting mission-critical customers around the world. He will also drive the future technical direction of the company – a pivotal role as the company remains at the forefront of innovation within the modern data stack while customer adoption surges.

Key Points: 
  • PHILADELPHIA, Feb. 1, 2024 /PRNewswire/ -- dbt Labs , the pioneer in analytics engineering, today announced the appointment of Mark Porter as Chief Technology Officer.
  • Porter will lead dbt Labs' engineering organization including the development, research and infrastructure teams, supporting mission-critical customers around the world.
  • "Mark has scaled and run many successful engineering organizations, and brings relevant experience on the commercial open source journey, " said Tristan Handy, founder and CEO of dbt Labs.
  • "I've followed dbt Labs for quite some time, and have seen first-hand just how integral dbt has become to the modern data stack," said Porter.